nausea%20-and-%20vomiting
NAUSEA & VOMITING
Nausea is the sensation felt immediately before vomiting.
Vomiting is a partially voluntary act of forceful expelling of stomach contents up to and out of the mouth that may or may not be preceded by nausea.
Retching or repetitive active contraction of the abdominal muscles occurs between nausea and vomiting.
Management includes correction of clinically relevant metabolic complications, pharmacological therapy and treatment of underlying cause.

Supportive Therapy

Rehydration

  • Patients with nausea and vomiting may become dehydrated and malnourished because of inadequate oral intake of fluid and nutrients, including electrolytes
  • Fluids and electrolytes, notably K+, are lost directly in the vomitus
  • Patients’ fluid and electrolyte status should be properly assessed to ensure adequate replacement
  • Normal saline solutions are commonly used, together with K+ supplementation as needed
  • In patients with gastric distension, a nasogastric tube may have to be inserted and tube output measured, so that appropriate replacement may be given
  • No study has compared the different fluid replacements for  nausea and vomiting of pregnancy

Other Supportive Measures

  • Other measures to reduce  nausea and vomiting may be useful, particularly in patients who have  nausea and vomiting of pregnancy
  • Pregnant patients should be advised to increase their rest, because tiredness may make nausea worse
  • Advise patients to avoid sensory stimuli that trigger symptoms eg strong odors
  • Enlist support from patient’s family and friends
  • Acupressure, acupuncture and acustimulation may be beneficial in patients with PONV and in women with nausea and vomiting of pregnancy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.